Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pulmonary arterial hypertension isn’t the only complex topic inside United Therapeutics’ disclosures. Investors hunting for revenue splits on treprostinil therapies, updates on organ manufacturing, or milestones in rare-disease trials often scroll through hundreds of pages. Our page delivers United Therapeutics SEC filings explained simply, turning every dense 10-K footnote or 8-K headline into plain-language insights. So when you search for “United Therapeutics 8-K material events explained,” you arrive at answers, not endless PDFs.
Stock Titan’s AI reads each United Therapeutics quarterly earnings report 10-Q filing the instant it posts to EDGAR, extracts cash-flow shifts, R&D spend, and segment growth, then produces a concise United Therapeutics earnings report filing analysis. The same engine delivers a United Therapeutics annual report 10-K simplified, flags evolving risk factors, and stitches multi-year trends—ideal for understanding United Therapeutics SEC documents with AI. Real-time alerts trigger the moment United Therapeutics Form 4 insider transactions real-time appear, ensuring you never miss executive moves.
Need deeper governance context? Track United Therapeutics insider trading Form 4 transactions or review United Therapeutics executive stock transactions Form 4 alongside the latest United Therapeutics proxy statement executive compensation. Whether you’re monitoring clinical trial spend, covenant triggers, or valuation drivers, every filing type—10-K, 10-Q, 8-K, S-8—arrives within seconds and is paired with expert commentary. Stop digging; let AI surface what matters most.
United Therapeutics (UTHR) reported an insider transaction by its President and COO. On 11/10/2025, the executive exercised stock options at $135.42 for 14,625 shares and at $146.03 for 7,875 shares, then sold the resulting shares at average prices of $452.0937 and $452.0397, respectively.
The trades were executed under a Rule 10b5-1 trading plan adopted on June 3, 2025, and were made through two trusts as disclosed. Following these transactions, the trusts reported 0 shares, and the filing shows 2,648 shares as directly owned. The related options were originally exercisable from 03/15/2023 and expire on 03/15/2026.
United Therapeutics (UTHR) reported an insider transaction by its CFO and Treasurer. On 11/10/2025, the officer exercised 21,000 stock options at $146.03 and sold the resulting shares in multiple tranches at weighted average prices ranging from $445.81 to $456.27, as detailed in the trade notes. Following these transactions, the officer beneficially owned 8,118 shares directly. The activity was conducted under a Rule 10b5-1 trading plan entered on August 5, 2025.
In addition, the filing shows 10,312 stock options beneficially owned after the reported transactions, with the exercised grant originally exercisable from March 15, 2020 and expiring March 15, 2027.
United Therapeutics (UTHR) reported insider transactions by its Chairperson & CEO. On 11/10/2025 and 11/11/2025, the reporting person exercised 8,000 stock options at an exercise price of $120.26 per share and sold 8,000 shares in open-market transactions.
Sales on 11/10/2025 included 3,500 shares at a weighted average price of $448.2675 (trades ranged from $448.00 to $448.53) and 500 shares at $449.22. Sales on 11/11/2025 included 1,097 shares at a weighted average price of $450.6427 (range $450.18–$451.06), 1,634 shares at $451.8664 (range $451.23–$452.09), and 1,269 shares at $452.7807 (range $452.305–$453.25).
The transactions were made under a pre-arranged Rule 10b5‑1 plan entered on May 2, 2025, which continues until the earlier of the tranche’s 294,000 expiring options being exhausted (expire March 15, 2026) or December 31, 2025. Following the transactions, directly held common stock was 130 shares, with additional indirect holdings of 166 (by spouse) and trust holdings of 324,518, 258,117, 45,596, and 15,962 shares. Remaining options beneficially owned were 106,000.
United Therapeutics (UTHR) reported insider transactions by a Director and Chairperson & CEO. On 11/06/2025 and 11/07/2025, the reporting person exercised 4,000 stock options each day at $120.26 per share and sold a total of 8,000 shares in multiple trades at weighted average prices between $446.00 and $452.21, pursuant to a pre‑arranged Rule 10b5‑1 trading plan.
Following the transactions, direct holdings were 130 shares. Indirect holdings included 166 shares by spouse and family trust positions of 324,518, 258,117, 45,596, and 15,962 shares. Derivative holdings showed 114,000 stock options remaining after the reported exercises.
The 10b5‑1 plan, entered on May 2, 2025, continues until the earlier of exhaustion of a tranche of 294,000 options expiring March 15, 2026, or December 31, 2025.
United Therapeutics (UTHR) reported insider transactions by its Chairperson & CEO. On Nov 4, 2025 and Nov 5, 2025, the insider exercised 4,000 stock options each day at an exercise price of $120.26 and sold 4,000 shares each day at weighted average prices ranging from approximately $432.53 to $442.262. These trades were made under a Rule 10b5-1 trading plan entered on May 2, 2025, which continues until the earlier of the exhaustion of a 294,000-option tranche expiring March 15, 2026 or December 31, 2025.
Following the reported transactions, direct holdings were 130 shares. The filing also lists additional indirect holdings by spouse and family trusts.
United Therapeutics (UTHR) disclosed that its CFO and Treasurer exercised 21,000 stock options at $146.03 and sold the resulting shares in multiple trades on November 4, 2025 under a Rule 10b5-1 trading plan entered on August 5, 2025.
The sales were executed in blocks at weighted average prices ranging from $432.0874 to $439.5102, covering all 21,000 shares acquired upon exercise. After these transactions, the reporting person directly owned 8,118 shares of common stock.
United Therapeutics (UTHR) Chairperson & CEO reported option exercises and open‑market sales under a pre‑arranged Rule 10b5‑1 plan. On 10/31/2025 and 11/03/2025, the insider exercised 4,000 stock options each day at an exercise price of $120.26 per share (8,000 total), then sold 4,000 shares each day in multiple trades.
Weighted average sale prices on 10/31/2025 included $447.826, $449.835, and $451.4864. On 11/03/2025, sales occurred at weighted averages of $433.7769, $434.3311, $438.624, $441.39, and $443.01. Following the transactions, direct holdings were 130 shares, with additional indirect holdings of 166 (by spouse) and trusts holding 324,518, 258,117, 45,596, and 15,962 shares. Derivative securities beneficially owned were 130,000 options after the 11/03 exercise. The trading plan, entered on May 2, 2025, continues until the earlier of exhaustion of a tranche of 294,000 options expiring March 15, 2026, or December 31, 2025.
United Therapeutics (UTHR) reported insider activity by its President and COO. On 11/03/2025, the reporting person exercised 14,625 stock options at $135.42 and 7,875 options at $146.03, then sold the resulting shares in multiple tranches. The sales were effected at weighted average prices that included $417.4965, $432.5476, and up to $441.9446, with individual trade ranges disclosed between $432.02 and $442.31.
The filing states these transactions were executed under a Rule 10b5‑1 trading plan entered on June 3, 2025. The options were exercised and shares sold through trusts for which the reporting person has investment and voting power as described, including a family trust. Following the transactions, the form shows 41,250 and 10,500 derivative securities (options) beneficially owned, as applicable to the noted trusts.
United Therapeutics (UTHR) disclosed a routine insider update. A company director reported a Form 4 transaction coded “G” involving 450 shares on 11/03/2025 at $0.00 per share. Following this activity, the director’s beneficial ownership stands at 4,190 shares, held directly.
United Therapeutics (UTHR) Chairperson & CEO reported Form 4 transactions under a pre-arranged Rule 10b5-1 plan. On 10/29/2025, she exercised 4,000 options at $120.26 and sold 1,100 shares at $433.31, 2,000 at $435.24, and 900 at $439.99. On 10/30/2025, she exercised another 4,000 options at $120.26 and sold 1,500 at $447.135, 541 at $448.425, 1,459 at a weighted average of $450.2338, and 500 at $451.29.
The filing shows 130 shares held directly after the reported trades and 138,000 stock options remaining. Indirect holdings include 166 shares by spouse and shares held across family trusts. The 10b5‑1 plan, entered on May 2, 2025, continues until the earlier of a 294,000-option tranche’s exhaustion (expiring March 15, 2026) or December 31, 2025.
FAQ
What is the current stock price of United Therapeutics (UTHR)?
What is the market cap of United Therapeutics (UTHR)?
